Nataliya Pasyechnikova

Nataliya Pasyechnikova

Auto-generated profile, based on publicly available information

Nataliya Pasyechnikova


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2018 in npj Regenerative Medicine
Verified
Journal Article
Open access
PDF file
MIM. Mirazul Islam
M. Mirazul Islam
OBOleksiy Buznyk
Oleksiy Buznyk
JRJagadesh C. Reddy
Jagadesh C. Reddy
NPNataliya Pasyechnikova
Nataliya Pasyechnikova
EAEmilio Alarcon
Emilio Alarcon
MGMay Griffith
May Griffith
The severe worldwide shortage of donor organs, and severe pathologies placing patients at high risk for rejecting conventional cornea transplantation, have left many corneal blind patients untreated. Following successful pre-clinical evaluation in mini-pigs, we tested a biomaterials-enabled pro-regeneration strategy to restore corneal integrity in an open-label observational study of six patients. Cell-free corneal implants comprising recombinant human collagen and phosphorylcholine were grafted by anterior lamellar keratoplasty into corneas of unilaterally blind patients diagnosed at high-risk for rejecting donor allografts. They were followed-up for a mean of 24 months. Patients with acute disease (ulceration) were relieved of pain and discomfort within 1–2 weeks post-operation. Patients with scarred or ulcerated corneas from severe infection showed better vision improvement, followed by corneas with burns. Corneas with immune or degenerative conditions transplanted for symptom relief only showed no vision improvement overall. However, grafting promoted nerve regeneration as observed by improved touch sensitivity to near normal levels in all patients tested, even for those with little/no sensitivity before treatment. Overall, three out of six patients showed significant vision improvement. Others were sufficiently stabilized to allow follow-on surgery to restore vision. Grafting outcomes in mini-pig corneas were superior to those in human subjects, emphasizing that animal models are only predictive for patients with non-severely pathological corneas; however, for establishing parameters such as stable corneal tissue and nerve regeneration, our pig model is satisfactory. While further testing is merited, we have nevertheless shown that cell-free implants are potentially safe, efficacious options for treating high-risk patients.

21 May 2015 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
OBOleksiy Buznyk
Oleksiy Buznyk
NPNataliya Pasyechnikova
Nataliya Pasyechnikova
MIM. Mirazul Islam
M. Mirazul Islam
SIStanislav Iakymenko
Stanislav Iakymenko
PFPer Fagerholm
Per Fagerholm
MGMay Griffith
May Griffith
Corneas with severe pathologies have a high risk of rejection when conventionally grafted with human donor tissues. In this early observational study, we grafted bioengineered corneal implants made from recombinant human collagen and synthetic phosphorylcholine polymer into three patients for whom donor cornea transplantation carried a high risk of transplant failure. These patients suffered from corneal ulcers and recurrent erosions preoperatively. The implants provided relief from pain and discomfort, restored corneal integrity by promoting endogenous regeneration of corneal tissues, and improved vision in two of three patients. Such implants could in the future be alternatives to donor corneas for high‐risk patients, and therefore, merits further testing in a clinical trial.

17 July 2014 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
NUNicolay Umanets
Nicolay Umanets
NPNatalya V. Pasyechnikova
Natalya V. Pasyechnikova
VNVladimir A. Naumenko
Vladimir A. Naumenko
PHPaul B. Henrich
Paul B. Henrich

1 March 2020 in Journal of Ocular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
AKAndrii R. Korol
Andrii R. Korol
TKTaras Kustryn
Taras Kustryn
OZOleg Zadorozhnyy
Oleg Zadorozhnyy
NPNatalya Pasyechnikova
Natalya Pasyechnikova
IKIgor Kozak
Igor Kozak
Purpose: To compare the 24-month efficacy of intravitreal ranibizumab and aflibercept in treatment-naive patients with myopic choroidal neovascularization (CNV). Methods: Ninety-six naive patients (97 eyes) with myopic CNV were included in this single-center study. Patients received intravitreal ranibizumab (IVR) or aflibercept (IVA) following a pro re nata regimen (PRN). Results: Fifty patients (50 eyes) received 0.5 mg IVR, 46 patients (47 eyes) received 2.0 mg of IVA. There was no significant between-group difference in mean decimal best-corrected visual acuity (BCVA) (P = 0.6) or mean central retinal thickness (CRT) (P = 0.9) at 24 months. The mean ± standard deviation (SD) BCVA at baseline in the IVR group was 0.21 ± 0.14 and 0.20 ± 0.14 in the IVA group. At month 24, BCVA was 0.43 ± 0.24 (P < 0.001) in the IVR group and 0.41 ± 0.2 (P < 0.001) in the IVA group. Baseline mean ± SD CRT was 318 ± 84 microns in the IVR group and 303 ± 65 microns in the IVA group. At month 24, CRT was 226 ± 31 microns in the IVR group (P < 0.001) and 224 ± 35 microns in the IVA group (P < 0.001). There were no significant differences in the mean number of injections between the IVR group and the IVA group (2.9 ± 1.2 vs. 2.8 ± 1.1), (P = 0.7). Conclusions: Our study demonstrates that ranibizumab and aflibercept in a PRN regimen lead to a significant increase of BCVA and decrease in central foveal thickness in treatment-naive patients with myopic CNV after 24 months.

1 July 2017 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
AKAndrii R Korol
Andrii R Korol
OZOleksandra Zborovska
Oleksandra Zborovska
TKTaras Kustryn
Taras Kustryn
ODOleksandra Dorokhova
Oleksandra Dorokhova
NPNataliya Pasyechnikova
Nataliya Pasyechnikova

Purpose:
The purpose of this study was to evaluate the potential benefits of intravitreal aflibercept injections for the treatment of choroidal neovascularization (CNV) secondary to chorioretinitis. Methods: In this uncontrolled, prospective cohort study, 15 eyes of 14 consecutive patients affected by CNV associated with ocular toxoplasmosis were treated with intravitreal aflibercept (2 mg) pro re nata and observed over a 12-month follow-up period. The primary outcome was the change in best-corrected visual acuity (BCVA) from baseline to month 12. Secondary outcomes included change in central retinal thickness (CRT) in the foveal area on optical coherence tomography (OCT) from baseline to month 12, the number of intravitreal aflibercept injections administered, and safety. Results: Mean (standard deviation [SD]) BCVA improved significantly from 0.36 (0.23) at baseline to 0.64 (0.3) at month 12 (P=0.0002). Mean (SD) CRT on OCT showed a reduction from 317 (74) µm at baseline to 254 (43) µm (P=0.0002) at month 12. A mean (SD) of 1.7 (0.5) injections (range, 1–2 injections) were performed during the study period. No cases of endophthalmitis, uveitis, stroke, or retinal detachment were noted. No patient demonstrated an intraocular pressure >20 mmHg at any study visit. Conclusion: Intravitreal aflibercept showed a positive clinical effect and was well tolerated for the treatment of CNV associated with chorioretinitis. The results could be helpful for selecting a treatment for CNV secondary to chorioretinitis.

10 May 2017 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Open access
PDF file
YAYassine Alibet
Yassine Alibet
GLGalyna Levytska
Galyna Levytska
NUNicolay Umanets
Nicolay Umanets
NPNatalya Pasyechnikova
Natalya Pasyechnikova
PHPaul B. Henrich
Paul B. Henrich
Background The literature is scant on the state of the ciliary body, its role in the development of rhegmatogenous retinal detachment (RRD) complicated by choroidal detachment (CD), and on ciliary body changes following the treatment aimed at resolving concomitant inflammation and choroidal attachment. This study assesses the anatomical position and thickness of the ciliary body and investigates the ciliary body changes after anti-inflammatory pre-vitrectomy treatment in RRD complicated by CD. Methods Forty-nine patients (49 eyes) with RRD complicated by CD underwent standard ophthalmological examination (including visual acuity assessment, biomicroscopy, ophthalmoscopy, and ocular tonometry) and ultrasound biomicroscopy of the ciliary body, choroid, and retina both before and following anti-inflammatory pre-vitrectomy treatment. Results At baseline, all subject eyes had ciliary body edema and detachment extending into the choroid. Ultrasonographic ciliary features included ciliary body edema and disorganization of the supraciliary layer of the pars plana, which was evident by the presence of multiple small oblique fibers. In all subject eyes, the treatment resulted in reattachment of the choroid and the ciliary body as well as a reduction in ciliary body edema (total mean ciliary thickness reduced from 0.83 (0.09) to 0.65 (0.09) mm, with a difference of 0.18 (0.07) mm, P < 0.001). Conclusions Preoperative anti-inflammatory treatment in RRD complicated by CD results in restoration of the anatomical position of the ciliary body and a statistically significant reduction in ciliary body edema.